Advertisement

Gilead CEO resigns amid pricing scrutiny

By Adam Rubenfire  |  February 01, 2016

Gilead Sciences, the Foster City, Calif.-based drugmaker under pressure for its hepatitis C drug pricing, announced late last week that longtime CEO John Martin will step down from that role, becoming executive chairman of the company.

High drug prices will be a big political issue in 2016

High drug prices will be a big political issue in 2016

By Steven Ross Johnson  |  January 01, 2016

High prescription drug prices will be a top-tier political issue in 2016 as the expected introduction of many expensive specialty medications to treat chronic conditions threatens to drive up healthcare spending.

How drug prices and payment reform are changing the pharmacy benefit business

How drug prices and payment reform are changing the pharmacy benefit business

By Bob Herman  |  September 26, 2015

The pharmacy benefit management industry has been quietly changing amid healthcare payment reforms and an increasingly fierce debate over drug prices. Now a leadership shuffle at Express Scripts has experts speculating that the days of PBMs as stand-alone companies may be numbered.

Pricey successor overtakes $1,000-per-pill Sovaldi

By Associated Press  |  July 13, 2015

Sovaldi, the $1,000 pill for hepatitis C, is no longer the favorite of patients and doctors. The new leading pill is more expensive, and the number of patients seeking a cure has surged.

Advertisement
Modern Healthcare Daily

Award winning coverage of healthcare business and policy news.

The Modern Healthcare app includes a personalized home screen, strong search functionality and immediate downloads from the industry's leading healthcare media brand.